GlassScriptPhysician profile
George Klafter
NPI 1114929635
$4,949.95
in general payments reported to CMS, 2019-2025
28 companies · $3,819 in 2025
The $3,819 reported for 2025 was more than what 89% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $78.94 · 2021: $384 · 2022: $32.51 · 2024: $408 · 2025: $3,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,309 · Food and Beverage: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,309.49 |
| Food and Beverage | $917.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,497.60 | 2025 | |
| Sumitomo Pharma America, INC. | $345.39 | 2024-2025 | Gemtesa |
| Axonics, INC. | $111.23 | 2021-2022 | |
| Tolmar, INC. | $105.85 | 2024-2025 | Eligard, Jatenzo |
| Myovant Sciences INC. | $103.61 | 2021 | |
| Boston Scientific Corporation | $101.55 | 2025 | Bulkamid |
| Myriad Genetic Laboratories, INC. | $97.77 | 2021-2025 | Prolaris |
| Travere Therapeutics, INC. | $67.83 | 2020-2021 | |
| Bluewind Medical | $53.67 | 2025 | Revi |
| Ferring Pharmaceuticals INC. | $48.05 | 2019-2025 | Adstiladrin |
| Astellas Pharma US INC | $45.00 | 2019 | |
| Bard Access Systems, INC. | $38.38 | 2019 | |
| Dendreon Pharmaceuticals LLC | $37.75 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $28.80 | 2020-2021 | |
| Allergan, INC. | $26.34 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $25.62 | 2021 | |
| Antares Pharma, INC. | $23.66 | 2021 | |
| Photocure INC | $22.85 | 2021 | |
| Neotract INC. | $21.29 | 2019 | |
| Olympus America INC. | $20.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.93 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.00 | 2019 | |
| Inspire Medical Systems, INC. | $17.37 | 2025 | Inspire |
| Procept Biorobotics Corporation | $16.93 | 2019 | |
| Merck Sharp & Dohme LLC | $14.99 | 2021 | |
| Pfizer INC. | $14.84 | 2021 | |
| Janssen Biotech, INC. | $14.48 | 2019 | |
| Endo Pharmaceuticals INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Klafter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.